Semaglutide vs liraglutide diabetes comparison

Semaglutide vs Victoza: weekly GLP-1 pathways compared with daily liraglutide

Compare semaglutide pathways and Victoza liraglutide with clinician-safe guidance on type 2 diabetes labels, SUSTAIN 10 evidence, weekly versus daily routines, switching, safety screening, pharmacy access, and online seller red flags.

Educational guideUpdated June 28, 2026

How to compare semaglutide with Victoza safely

Name the exact product first: Ozempic, Wegovy, Rybelsus, compounded semaglutide when clinically and legally appropriate, Victoza liraglutide, Saxenda liraglutide, or another clinician-reviewed pathway.

Match the goal to the label context: adult type 2 diabetes care, pediatric type 2 diabetes questions, chronic weight management, cardiovascular-risk context, kidney-risk context, medication access, or side-effect management.

Use SUSTAIN 10 carefully: it compared once-weekly semaglutide 1.0 mg with once-daily liraglutide 1.2 mg in a studied adult type 2 diabetes population, not every semaglutide product, every liraglutide dose, or a no-prescription switching plan.

Review safety before switching: thyroid C-cell tumor contraindication language, pancreatitis symptoms, gallbladder disease, kidney or dehydration risk, retinopathy or vision changes, pregnancy plans, severe stomach-emptying symptoms, allergies, and insulin or sulfonylurea use.

Avoid no-prescription GLP-1 sellers, “generic Ozempic” or “generic Victoza” claims, research-use peptides, hidden pharmacy sourcing, dose charts without clinician review, and guaranteed weight-loss advertising.

Direct answer

Semaglutide and Victoza are related GLP-1 discussions, but they are not the same medication. Semaglutide is an active ingredient used in products such as Ozempic for type 2 diabetes and Wegovy for chronic weight management, while Victoza contains liraglutide and is labeled for type 2 diabetes care in adults and pediatric patients age 10 years and older, plus cardiovascular-risk reduction in adults with type 2 diabetes and established cardiovascular disease. In SUSTAIN 10, once-weekly semaglutide 1.0 mg lowered A1C and body weight more than once-daily liraglutide 1.2 mg over 30 weeks in adults with type 2 diabetes on oral diabetes medicines, but semaglutide also had more gastrointestinal adverse events and discontinuations. Individual choice still depends on diagnosis, age, glucose history, other diabetes medicines, side effects, label fit, coverage, pharmacy access, and clinician review.

Product identity

Semaglutide is an active ingredient; Victoza is the liraglutide brand

A useful comparison starts by separating active ingredient, brand, route, and intended use. Semaglutide appears in different products with different labels, including Ozempic for adults with type 2 diabetes, Wegovy for chronic weight management and selected cardiometabolic contexts, and Rybelsus as oral semaglutide for type 2 diabetes. Victoza is branded liraglutide, a once-daily GLP-1 receptor agonist labeled for type 2 diabetes glycemic control in adults and pediatric patients age 10 years and older, and for reducing major cardiovascular-event risk in adults with type 2 diabetes and established cardiovascular disease.

A patient asking about semaglutide versus Victoza should specify whether the real question is Ozempic, Wegovy, Rybelsus, compounded semaglutide, Victoza, Saxenda, or a diabetes-medication switch.
Victoza is not a Peptide12 catalog product, but patients often compare it with semaglutide when A1C, weight trend, coverage, supply, side effects, or switching questions come up.
Compounded semaglutide, when considered under an individualized prescription and appropriate legal conditions, is not an FDA-approved finished drug product and should not be marketed as generic Ozempic, Wegovy, Rybelsus, or Victoza.

Evidence and expectations

SUSTAIN 10 favored semaglutide for A1C and weight in a studied diabetes population

SUSTAIN 10 was a phase 3b open-label trial in 577 adults with type 2 diabetes whose A1C remained above goal on one to three oral diabetes medicines. Over 30 weeks, once-weekly semaglutide 1.0 mg reduced mean A1C by 1.7% versus 1.0% with once-daily liraglutide 1.2 mg, and mean body weight by 5.8 kg versus 1.9 kg. The trial supports semaglutide as a strong GLP-1 option in that setting, but it does not replace patient-specific review or prove that every patient should switch from Victoza.

The trial population was adults with type 2 diabetes on oral diabetes medicines; it was not a pediatric trial, a weight-management-label trial, or a study of no-prescription GLP-1 products.
SUSTAIN 10 also reported more gastrointestinal adverse events and more premature treatment discontinuation with semaglutide than liraglutide, so tolerability matters alongside average A1C and weight results.
A clinician should review prior GLP-1 tolerance, current dose, last injection timing, glucose readings, A1C trend, side effects, insurance or pharmacy access, and follow-up capacity before changing therapy.

Safety review

The GLP-1 checklist overlaps, but diabetes context can change the plan

Semaglutide and liraglutide decisions should include boxed-warning counseling about thyroid C-cell tumor findings in rodents, contraindications involving medullary thyroid carcinoma or MEN 2, pancreatitis symptoms, gallbladder disease, kidney injury risk when severe gastrointestinal symptoms cause dehydration, serious hypersensitivity, pregnancy and breastfeeding questions, and severe gastrointestinal disease or stomach-emptying symptoms. Diabetes-focused patients may also need A1C or glucose logs, kidney function, diabetic retinopathy or vision-change review, and medication coordination if insulin or sulfonylureas are used.

Severe persistent abdominal pain, repeated vomiting, dehydration symptoms, allergic symptoms, vision changes, fainting, chest symptoms, severe mood changes, or possible hypoglycemia should not be handled as routine online shopping questions.
Pediatric type 2 diabetes care, type 1 diabetes, diabetic ketoacidosis history, complex insulin regimens, eating-disorder history, bariatric surgery history, pregnancy plans, breastfeeding, or gastroparesis symptoms need careful clinician review.
Do not stack Victoza with semaglutide unless a qualified prescriber gives a documented, patient-specific transition plan; routine GLP-1 overlap can increase side-effect risk without clear benefit.

Access and pharmacy quality

Online access should distinguish branded, compounded, and unsafe GLP-1 claims

Many semaglutide versus Victoza searches are really access questions: one medicine is not covered, a pharmacy is out of stock, side effects are limiting, a daily routine is inconvenient, or the patient is comparing cash-pay options. A responsible online clinic should distinguish FDA-approved branded products from individualized compounded prescriptions when clinically and legally appropriate, and from unsafe marketplace products. No seller should use semaglutide or Victoza name recognition to imply an unverified vial has the same label, evidence, quality oversight, or approved status.

Ask who reviews the intake, what diagnosis or goal is being treated, which pharmacy dispenses, how labels and storage are handled, and how side effects or refill gaps are followed up.
Avoid “generic Ozempic,” “generic Victoza,” “semaglutide without prescription,” “liraglutide research peptide,” or GLP-1 checkout pages that hide prescriber or pharmacy identity.
If branded access is limited, the next step is a clinician-led alternative plan—not mixing GLP-1s, stretching doses, copying conversion charts, or buying unlabeled vials online.

Patient safety checklist

Questions to ask before comparing semaglutide with Victoza

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Is the goal type 2 diabetes treatment, chronic weight management, cardiovascular or kidney-risk context, medication access, side-effect management, or another clinician-reviewed issue?

✓

Which semaglutide pathway is being discussed: Ozempic, Wegovy, Rybelsus, another branded product, or an individualized compounded semaglutide prescription when appropriate?

✓

Is Victoza being used for type 2 diabetes, and are age, A1C trend, glucose readings, insulin or sulfonylurea use, kidney function, cardiovascular history, and eye history being reviewed?

✓

Do I have a personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, gallbladder disease, kidney problems, retinopathy, severe gastrointestinal disease, pregnancy plans, breastfeeding, or prior allergic reaction?

✓

If switching, when should the prior GLP-1 stop, when should the new plan begin, and what symptoms should pause escalation or trigger urgent care?

✓

Is the product FDA-approved and branded, compounded for an individualized need, or a no-prescription seller product that should be avoided?

✓

What is the total cost including clinician review, medication, supplies, shipping, labs, follow-up, replacement policy, and refill support?

✓

Who coordinates with my primary-care clinician, endocrinologist, cardiologist, ophthalmologist, nephrologist, or pediatric clinician if high-risk history is present?

FAQs

Short answers for patients

Is semaglutide the same as Victoza?

No. Semaglutide and liraglutide are different GLP-1 receptor agonist active ingredients. Victoza contains liraglutide. Semaglutide appears in products with different labels, including Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as oral semaglutide for type 2 diabetes.

Which lowered A1C more in SUSTAIN 10: semaglutide or Victoza?

In SUSTAIN 10, once-weekly semaglutide 1.0 mg lowered mean A1C more than once-daily liraglutide 1.2 mg over 30 weeks in adults with type 2 diabetes on oral diabetes medicines. Individual choice still depends on diagnosis, age, prior response, side effects, other diabetes medicines, access, and clinician judgment.

Is semaglutide better than Victoza for weight loss?

SUSTAIN 10 reported greater average body-weight reduction with semaglutide than liraglutide in adults with type 2 diabetes. But Ozempic, Rybelsus, and Victoza are diabetes medications, while Wegovy is the semaglutide brand with chronic weight-management labeling. Weight-related care should be matched to label context, medical history, and clinician review.

Can I switch from Victoza to semaglutide online?

A licensed clinician may consider a switch, but it should not be done by copying a dose chart. The plan should account for the last dose date, current dose, side effects, glucose readings, insulin or sulfonylurea use, kidney or dehydration risk, pregnancy plans, pharmacy access, and follow-up timing.

Can Victoza and semaglutide be taken together?

Patients generally should not stack two GLP-1 receptor agonists. Combining Victoza with semaglutide can increase gastrointestinal and hypoglycemia-related risks without a clear routine benefit. Any transition should be coordinated by the prescribing clinician.

What are red flags for online semaglutide or Victoza alternatives?

Red flags include no-prescription checkout, “generic Ozempic” or “generic Victoza” claims, research-use GLP-1 vials, hidden pharmacy sourcing, missing clinician review, guaranteed weight-loss promises, unclear storage or lot information, and claims that compounded GLP-1s are FDA-approved finished drugs.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

PubMed: SUSTAIN 10 semaglutide versus liraglutide in type 2 diabetes DailyMed: Ozempic (semaglutide) prescribing information DailyMed: Victoza (liraglutide) prescribing information FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss FDA: Compounding and the FDA questions and answers Peptide12: Compounded semaglutide injection Peptide12: Ozempic prescription online Peptide12: Wegovy prescription online Peptide12: Ozempic vs Victoza Peptide12: Wegovy vs Victoza Peptide12: Semaglutide vs Saxenda Peptide12: Semaglutide vs Trulicity Peptide12: GLP-1 glucose monitoring Peptide12: Fake GLP-1 pharmacy checklist Peptide12: How online peptide therapy works